Journals / Experimed / 2022 / Cilt: 12 - Sayı: 3

Shotgun Lipidomics Elucidates the Lipidome Alterations of the Mcl-1 Inhibitor S63845 in AML Cell Lines with a Focus on Sphingolipids

Journal
Experimed
Pages
209–214
Publication Date
2022-12-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

More importantly, the study suggested S63845 to differentially affect the lipid profiles of AML cell lines.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Acute myeloid leukemia (AML) is a vigorous type of leukemia requiring effective treatment.
📊
Key Findings & Data:Myeloid cell leukemia-1 (Mcl-1) is an anti-apoptotic molecule that is upregulated in AML and is studied as a target for treatment.
💡
Conclusion & Impact:More importantly, the study suggested S63845 to differentially affect the lipid profiles of AML cell lines.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Mcl-1 · small molecule inhibitors · S63845

Abstract

Objective: Acute myeloid leukemia (AML) is a vigorous type of leukemia requiring effective treatment. Myeloid cell leukemia-1 (Mcl-1) is an anti-apoptotic molecule that is upregulated in AML and is studied as a target for treatment. The specific Mcl-1 inhibitor, S63845, has antiproliferative effects on AML cells. Bioactive sphingolipids have crucial roles in cells and regulate Mcl-1 stability. This study aimed to elucidate the changes in lipid profiles of AML cell lines in response to Mcl-1 inhibitor S63845 treatment, with a special focus on sphingolipids.Materials and Methods: The cytotoxic effects of S63845 were identified in the AML cell lines MV4-11, HL60, and KG1 using the MTT cell proliferation assay. Lipidome analysis was conducted by quantitative shotgun lipidomics covering 378 individual lipid species in 26 classes within the major lipid categories.Results: The IC50 values of S63845 have been calculated as 7 nM for MV4-11, 53 nM for HL60, and 479 nM for KG1. The lipidome results reveal the S63845 treatment to increase ceramide (Cer) levels in the MV4-11 and KG1 cell lines at the expense of downstream sphingolipids while increasing the hexosylceramide (HexCer) levels in the HL60 cell line at the expense of the Cer and sphingomyelin (SM).Conclusion: This study showed S63845 to be able to suppress cell proliferation by altering lipid compositions in AML cell lines. More importantly, the study suggested S63845 to differentially affect the lipid profiles of AML cell lines.

🔖

Cite This Article

YANDIM, M. K., BİLGİN, M. (2022). Shotgun Lipidomics Elucidates the Lipidome Alterations of the Mcl-1 Inhibitor S63845 in AML Cell Lines with a Focus on Sphingolipids. Experimed, Cilt: 12 - Sayı: 3, 209–214. https://ajindex.com/articles/878276

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Padmakumar D, Chandraprabha VR, Gopinath P, Vimala Devi ART, Anitha GRJ, Sreelatha MM, et al. A concise review on the molecular genetics of acute myeloid leukemia. Vol. 111, Leukemia Research. Elsevier Ltd
  2. [CrossRef] google scholar 2. Newell LF, Cook RJ. Advances in acute myeloid leukemia. Vol. 16. 375, BMJ (Clinical research ed.). NLM (Medline)
  3. p. n2026. [CrossRef] google scholar 3. Pearson JM, Tan SF, Sharma A, Annageldiyev C, Fox TE, Abad JL, et al. Ceramide analogue SACLAC modulates sphingolipid levels and 17. MCL-1 splicing to induce apoptosis in acute myeloid leukemia. Mol Cancer Res 2020
  4. 18(3): 352-63. [CrossRef] google scholar 4. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable 18. and effective in diverse cancer models. Nature 2016
  5. 538(7626): 477-82. [CrossRef] google scholar 5. Bolomsky A, Vogler M, Köse MC, Heckman CA, Ehx G, Ludwig H, et al. MCL-1 inhibitors, fast-lane development of a new class of anti- 19. cancer agents. J Hematol Oncol 2020
  6. [CrossRef] google scholar 6. Wang H, Guo M, Wei H, Chen Y. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol 2021
  7. 14(1): 67. [CrossRef] google scholar 7. Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has 21. potent activity in pre-clinical models of acute myeloid leukemia. Leukemia 2019
  8. 33(4): 905-17. [CrossRef] google scholar 8. Malyukova A, Ujvari D, Yektaei-Karin E, Zovko A, Madapura HS, Keszei M, et al. Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects 22. on CML cells. Cell Death Dis 2021
  9. 12(10). [CrossRef] google scholar 9. Stefanko A, Thiede C, Ehninger G, Simons K, Grzybek M. Lipidomic approach for stratification of acute myeloid leukemia patients. 23. PLoS One 2017
  10. 12(2). [CrossRef] google scholar 10. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004
  11. 4(8): 604-16. [CrossRef] 24. google scholar 11. Powell JA, Lewis AC, Zhu W, Toubia J, Pitman MR, WallingtonBeddoe CT, et al. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. Blood 2017
  12. [CrossRef] google scholar 12. Tan SF, Liu X, Fox TE, Barth BM, Sharma A, Turner SD, et al. Acid ceramidase is upregulated in AML and represents a novel 26. therapeutic target. On